MARKET

BNTX

BNTX

BIONTECH
NASDAQ

Real-time Quotes | Nasdaq Last Sale

151.54
+10.82
+7.69%
After Hours: 151.20 -0.34 -0.22% 19:59 04/16 EDT
OPEN
141.49
PREV CLOSE
140.72
HIGH
152.32
LOW
141.49
VOLUME
4.62M
TURNOVER
--
52 WEEK HIGH
152.32
52 WEEK LOW
37.00
MARKET CAP
36.60B
P/E (TTM)
-372.5172
1D
5D
1M
3M
1Y
5Y
UPDATE 1-Japanese PM, Pfizer CEO discuss delivery of additional vaccine doses in 2021 to Japan
UPDATE 1-Japanese PM, Pfizer CEO discuss delivery of additional vaccine doses in 2021 to Japan
reuters.com · 2h ago
U.S. administers 205.9 mln doses of COVID-19 vaccines
reuters.com · 5h ago
Moderna cuts UK COVID vaccine deliveries as pregnant women told mRNA jabs are safe
The Moderna jab, which works in a similar way to the Pfizer vaccine, uses synthetic messenger RNA (mRNA) technology that can be quickly tweaked to address new mutations of a virus.
Yahoo Finance UK · 11h ago
Dubai expands vaccine eligibility in certain cases
reuters.com · 13h ago
Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra
Zacks · 1d ago
BioNTech SE ADR rises Friday, outperforms market
The BioNTech SE ADR advanced 7.69% to $151.54 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...
marketwatch.com · 1d ago
Senators urge Biden to back temporary WTO waiver of IP rights to speed vaccine access
reuters.com · 1d ago
BRIEF-Canada says Pfizer has asked to expand usage of its COVID-19 vaccine 12-year-olds and up
reuters.com · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNTX. Analyze the recent business situations of BIONTECH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BNTX stock price target is 126.51 with a high estimate of 135.08 and a low estimate of 109.54.
EPS
Institutional Holdings
Institutions: 242
Institutional Holdings: 21.81M
% Owned: 9.03%
Shares Outstanding: 241.52M
TypeInstitutionsShares
Increased
41
3.07M
New
80
2.22M
Decreased
47
6.73M
Sold Out
34
1.04M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
  • All
  • Financials
  • Insiders
More
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Webull offers kinds of BioNTech SE - ADR stock information, including NASDAQ:BNTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNTX stock methods without spending real money on the virtual paper trading platform.